This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
MOR Overzicht aandelen
Engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States.
| Sneeuwvlok Score | |
|---|---|
| Waardering | 1/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 2/6 |
| Dividenden | 0/6 |
MorphoSys AG Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | €18.96 |
| 52 Week Hoogtepunt | €19.50 |
| 52 Week Laag | €4.19 |
| Bèta | 0.67 |
| 11 maand verandering | 1.94% |
| 3 maanden verandering | 5.69% |
| 1 Jaar Verandering | 150.79% |
| 33 jaar verandering | 38.65% |
| 5 jaar verandering | -36.95% |
| Verandering sinds IPO | -26.57% |
Recent nieuws en updates
Recent updates
MorphoSys: Hold Rating Until The Novartis Deal Closes
May 01Novartis And MorphoSys Are A Perfect Match
Feb 06MorphoSys: Positive Pelabresib Data Finally Unlocking Upside
Jan 18MorphoSys updates Q2 & FY22 guidance below prior provided levels
Jul 26MorphoSys May Not Recover From Adventurous Constellation Buyout
May 04Sierra Oncology's Strong Data In Myelofibrosis Challenges MorphoSys And Incyte
Jan 28Incyte and MorphoSys presents new three-year data for blood cancer therapy
Jun 04MorphoSys reports Q1 results
May 05MorphoSys AG appoints Sangamo 's Sung Lee as new CFO
Jan 06MorphoSys AG (MOR) Investor Presentation - Slideshow
Dec 08MorphoSys AG 2020 Q3 - Results - Earnings Call Presentation
Nov 22MorphoSys reports Q3 results
Nov 11Rendement voor aandeelhouders
| MOR | US Biotechs | US Markt | |
|---|---|---|---|
| 7D | 1.9% | -0.2% | -0.4% |
| 1Y | 150.8% | 22.1% | 34.1% |
Rendement versus industrie: MOR exceeded the US Biotechs industry which returned 14.8% over the past year.
Rendement versus markt: MOR exceeded the US Market which returned 15.9% over the past year.
Prijsvolatiliteit
| MOR volatility | |
|---|---|
| MOR Average Weekly Movement | 3.3% |
| Biotechs Industry Average Movement | 10.0% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiele aandelenkoers: MOR has not had significant price volatility in the past 3 months.
Volatiliteit in de loop van de tijd: MOR's weekly volatility has decreased from 12% to 3% over the past year.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 1992 | 464 | Arkadius Pichota | www.morphosys.com |
MorphoSys AG Samenvatting
| MOR fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$2.78b |
| Inkomsten(TTM) | -US$513.62m |
| Inkomsten(TTM) | US$264.68m |
10.5x
P/S-verhouding-5.4x
Koers/WinstverhoudingIs MOR overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| MOR resultatenrekening (TTM) | |
|---|---|
| Inkomsten | €241.47m |
| Kosten van inkomsten | €60.14m |
| Brutowinst | €181.33m |
| Overige uitgaven | €649.90m |
| Inkomsten | -€468.57m |
Laatst gerapporteerde inkomsten
Mar 31, 2024
Volgende inkomensdatum
Aug 07, 2024
| Winst per aandeel (EPS) | -12.44 |
| Brutomarge | 75.09% |
| Nettowinstmarge | -194.05% |
| Schuld/Eigen Vermogen Verhouding | -658.0% |
Hoe presteerde MOR op de lange termijn?
Bekijk historische prestaties en vergelijking